Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics technology gets double green light - next stop human studies

Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells)
woman examining her face in the mirror
The company's first product will be a skincare cosmetic

SkinBioTherapeutics PLC (LON:SBTX) said its SkinBiotix technology has passed two additional and final toxicity tests, meaning it is safe to use in the company’s three target markets.

Researchers at Charles River Laboratories assessed for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells).

Prior to that, SkinBiotix was found not to be cytotoxic, which in layman’s terms meant it didn’t kill cells it came in contact with.

Focusing on efficacy

"Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focusing on further proving its efficacy,” said Dr Catherine O'Neill, chief executive of SkinBioTherapeutics.

The company is focused on developing products and treatments that effect the portion of the human microbiome that resides on the skin.

This is a mix of bacteria, yeasts, and parasites that live on the body’s biggest organ.  Sounds gross, but this microbial ecosystem is thought to be key to skin health.

READ: SkinBiotherapeutics readying for cosmetic cream launch after safety test success

Based on the work of CEO O’Neill at Manchester University, the SkinBiotix platform is protected by three patent families and 18 patent applications.

It is also supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

As mentioned above, the firm is developing three products that manage, protect and restore the body’s outer layer.

First cab off the rank

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.

WATCH: SkinBioTherapeutics' Dr Cath O'Neill named one of healthcare's top movers and shakers

The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.

Human trials

Earlier this week SkinBioTherapeutics said it expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’ commercialisation talks.

Tentative discussions have already begun, said CEO O’Neill, but human data is crucial to the process. 

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

In the release Thursday, the company said it was confident of human studies getting underway next year.

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use